On October 23, 2016, the first China oncology clinical trial summit was solemnly held at the Beijing National Conference Center. The forum attracted many oncologists from all over the country to discuss the problems existing in the clinical development of new anti-tumor drugs, to perfect the new drug approval standards and the future development direction. Dr. Lu, the president and chief scientific officer of CHIPSCREEN BIOSCIENCES, was invited to attend the conference and give a report on " how to comprehensively design clinical development of innovative drugs from an enterprise perspective".

In recent years, the speed of research and development of new anti-tumor drugs in our country has obviously accelerated. A large number of anti-tumor drugs with new mechanisms of action are continuously entering clinical trials. The traditional concepts and methods of clinical trials of cytotoxic anti-tumor drugs can no longer meet the needs of clinical trials of new drugs. At the same time, with the increase of the state's supervision on clinical trials, the requirements for the quality of clinical trials are also getting higher and higher. Under the strong support of a series of national policies and funds for " major new drug discovery" and major scientific and technological projects, clinical trials of anti-tumor drugs in our country are in a historical opportunity period of full development. It is against this background that the Chinese pharmaceutical anti-tumor drug Committee initiated the summit, which was widely recognized by experts in CFDA Drug Review Center and anti-tumor new drug research and development field. The summit has played an active role in promoting the healthy development of clinical trials of anti-tumor new drugs in our country.